cliffwatch

amlodipine besylate · Cmp Dev Llc · NDA 214439

Norliqva

Earliest generic entry, as listed
24 Feb 2041

Blocked by patent: US 11253474, US 11253474, US 11253474, US 11458095, US 11458095, US 11458095, US 11723866, US 11723866, US 11723866, US 12005141, US 12005141, US 12005141, US 12226528, US 12226528, US 12226528, US 12440441, US 12440441, US 12440441.

Listed patents · 18 unexpired

PatentClaimsExpires
US 11253474product, use U-330924 Feb 2041
US 11253474product, use U-331124 Feb 2041
US 11253474product, use U-331024 Feb 2041
US 11458095product, use U-330924 Feb 2041
US 11458095product, use U-331024 Feb 2041
US 11458095product, use U-331124 Feb 2041
US 11723866product, use U-331124 Feb 2041
US 11723866product, use U-331024 Feb 2041
US 11723866product, use U-330924 Feb 2041
US 12005141product, use U-331024 Feb 2041
US 12005141product, use U-331124 Feb 2041
US 12005141product, use U-330924 Feb 2041
US 12226528product, use U-330924 Feb 2041
US 12226528product, use U-331024 Feb 2041
US 12226528product, use U-331124 Feb 2041
US 12440441product, use U-331024 Feb 2041
US 12440441product, use U-331124 Feb 2041
US 12440441product, use U-330924 Feb 2041

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
214439 · 001 · RLDsolution, oralEQ 1MG BASE/ML24 Feb 2041